The purpose of this study is to evaluate the efficacy of RO7837195 compared with placebo in participants with moderately to severely active ulcerative colitis for whom prior treatment with conventional and/or advanced therapies has failed.
Diagnosis of ulcerative colitis (UC) established at least 3 months
Moderately to severely active UC assessed by mMS
Inadequate response, loss of response, or intolerance to conventional or advanced therapies for UC
Prior extensive colonic resection, subtotal or total colectomy, or planned surgery for UC
Diagnosis of Crohn's disease or indeterminate colitis
Treatment with an advanced therapy targeted at tumor necrosis factor-like cytokine 1A (TL1a)
Inadequate response, loss of response, or intolerance to treatment of UC with an advanced therapy targeted at IL-12 and/or IL-23
Genentech, Inc.
Lead sponsor